What's in Mylan Inc.'s pipeline?

Mylan Inc. has 25 drugs in our index: 7 marketed, 0 filed, 9 in Phase 3, 5 in Phase 2, 4 in Phase 1.

Which companies overlap with Mylan Inc.'s portfolio?

Top competitors by shared drug class: Celltrion, Pfizer, Novo Nordisk A/S, Eli Lilly and Company, Medical University of Vienna.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/mylan-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Mylan Inc. — Portfolio Competitive Intelligence Brief

Mylan Inc. pipeline: 7 marketed, 0 filed, 9 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

7 marketed 0 filed 9 Phase 3 5 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Topical Antimicrobial/Antifungal Medications	Topical Antimicrobial/Antifungal Medications	marketed	Topical antimicrobial/antifungal agents (multiple classes)		Dermatology/Infectious Disease
TOBI® PODHALER®	TOBI® PODHALER®	marketed
Cayston®	Cayston®	marketed	Monobactam antibiotic	Bacterial penicillin-binding proteins (PBPs)	Respiratory / Infectious Disease
Humira® (Adalimumab)	Humira® (Adalimumab)	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)	Immunology
Sulfamylon® For 5 % Topical Solution	Sulfamylon® For 5 % Topical Solution	marketed	Sulfonamide antimicrobial agent	Dihydropteroate synthase (bacterial folate synthesis pathway)	Dermatology / Burn Care / Infectious Disease
Dymista	Dymista	marketed			Other
Bethkis®	Bethkis®	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit	Infectious Disease / Pulmonary
MYL-1401H	MYL-1401H	phase 3	HER2-targeted monoclonal antibody (trastuzumab biosimilar)	HER2 (human epidermal growth factor receptor 2)	Oncology
MYL- 1401O	MYL- 1401O	phase 3	Monoclonal antibody (bevacizumab biosimilar)	VEGF (Vascular Endothelial Growth Factor)	Oncology
Mylan's insulin glargine	Mylan's insulin glargine	phase 3	Insulin analog	Insulin receptor	Diabetes
MYL-1401A (Adalimumab)	MYL-1401A (Adalimumab)	phase 3	TNF-α inhibitor (monoclonal antibody biosimilar)	TNF-α (Tumor Necrosis Factor-alpha)	Immunology
FlexPen NovoLog®	FlexPen NovoLog®	phase 3	Rapid-acting insulin analog	Insulin receptor	Diabetes

Therapeutic area mix

Diabetes · 3
Oncology · 2
Other · 2
Immunology · 2
Cardiovascular · 1
Respiratory / Infectious Disease · 1
Dermatology / Burn Care / Infectious Disease · 1
Dermatology/Infectious Disease · 1
Infectious Disease / Pulmonary · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Celltrion · 3 shared drug classes
Pfizer · 3 shared drug classes
Novo Nordisk A/S · 2 shared drug classes
Eli Lilly and Company · 2 shared drug classes
Medical University of Vienna · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes
Chong Kun Dang Pharmaceutical · 2 shared drug classes
Janssen Pharmaceutical K.K. · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Mylan Inc.:

Cite this brief

Drug Landscape (2026). Mylan Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mylan-inc. Accessed 2026-05-14.